Editorials

Statins and primary prevention of cardiovascular events

BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2576 (Published 14 November 2008) Cite this as: BMJ 2008;337:a2576
  1. Norbert Donner-Banzhoff, professor1,
  2. Andreas Sönnichsen, professor2
  1. 1Department of General Practice, University of Marburg, D-35032 Marburg, Germany
  2. 2Institute of General Practice, Paracelsus Medical University, A-5020 Salzburg, Austria
  1. Norbert{at}med.uni-marburg.de

    No change in strategy is needed despite the hype surrounding the recent JUPITER study

    This week, the New England Journal of Medicine published the randomised controlled trial JUPITER,1 which compared rosuvastatin (20 mg daily) with placebo in 18 000 patients with no apparent vascular disease, low density lipoprotein cholesterol (LDL-C) of less than 3.4 mmol/l (130 mg/dl), and high sensitivity C reactive protein concentrations of 2.0 mg/l or higher. The combined primary end point was myocardial infarction, stroke, arterial revascularisation, hospital admission for unstable angina, or death from cardiovascular causes. The trial was stopped after a median of two years after a highly significant improvement in the primary end point with rosuvastatin (hazard ratio 0.56; 95% confidence interval 0.46 to 0.69; P<0.00001). It is hardly surprising that the JUPITER study is seen by many as opening the door to new avenues to prevention.

    What do the results mean? Do we really have to change our ways of targeting our preventive efforts—for example, measure high sensitivity C reactive protein on a regular basis? …

    Sign in

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe